Technology Licensing opportunities

Available technologies

Clear search
Novel platform for vaccine development using modified Viral-like Particles (VLPs)

A novel platform for production of Viral-like Particles (VLPs) used as a single vaccine against a range of viruses, including HIV, HPV, or Ebola. The invention combines two technical innovations; core platform to generate non-infectious VLPs based on the modification of Mumps or Parainfluenza 5 viruses, and a ‘pseudotyping’ technology to incorporate viral glycoproteins of choice on the surface of VLPs. As a proof of concept, the platform was used in development of modified VLPs against HIV. When used as a vaccine, VLPs boosted the production of anti-HIV antibodies better than the native virus.

SPARTA: Single Particle Automated Raman Trapping Analysis

SPARTA™ is a comprehensive nanoparticle analysis platform based on Raman spectroscopy providing simultaneous size, composition, and functionalisation analysis, as well as allowing live monitoring of dynamic reactions occurring on the surface of individual particles.

Biomimetic osteochondral scaffold

A novel multi-zonal anisotropic osteochondral scaffold has been developed which mimics the natural structure of articular cartilage with zone specific mechanical and biological properties

Novel phage/AAV delivery vector for gene therapy, medical imaging and vaccine delivery

The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.

Novel large-scale method of production of AAVs

A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.

Novel multifunctional bacteriophages

Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.

MicroRNA plasma markers for preterm labour

Suite of microRNAs for predicting cervical shortening and preterm birth that can be measured from blood samples taken in early pregnancy (from gestation week 12 onwards).

Novel protein fragment of von Willebrand’s factor for treating VWD and haemophilia A

Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.

3D Printing with polygrain lattices

Enables the production of lightweight but tough and damage tolerant structures

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London